US Stock Market Move | ADC drug's new indication achieves "global first launch" in China. Astrazeneca PLC Sponsored ADR (AZN.US) rose nearly 5% in early trading.

22:02 27/03/2026

On Friday, AstraZeneca (AZN.US) rose nearly 5% in early trading, reaching $192.17.

On Friday, Astrazeneca PLC Sponsored ADR (AZN.US) rose nearly 5% in early trading, reaching $192.17. On the news front, on March 27, Astrazeneca PLC Sponsored ADR announced that trastuzumab deruxtecan (Enhertu), a drug jointly developed with Daiichi Sankyo, has officially been approved by the Chinese National Medical Products Administration for use in neoadjuvant therapy for high-risk HER2-positive stage II or III breast cancer in adult patients. This is the first global approval for this indication, with China approving it before other global markets such as the US and Europe. Neoadjuvant therapy is anti-tumor treatment given before surgery. This drug is also the first and only ADC drug approved globally for neoadjuvant therapy in HER2-positive breast cancer.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.

Energy crisis does not hinder the expansion ambition: Microsoft Corporation (MSFT.US) increases investment in Japan by $10 billion, joining forces with SoftBank and Sakura to build AI cloud infrastructure.

China Galaxy Securities: High oil prices fluctuate, focus on alternative routes for oil.

Sinolink: Collaborative computing included in national strategy, multi-industry resonance on the same frequency.